<DOC>
	<DOCNO>NCT00251537</DOCNO>
	<brief_summary>This pilot study assess safety antiretroviral activity naturally occur substance know Leukotriene B4 ( LTB4 ) . The aim study determine effect LTB4 viral load period 6 week , 4 week active treatment 2 additional week end active treatment safety follow-up . 40 patient seven clinic Canada randomize three treatment arm , either two dos LTB4 placebo . Study drug administer intravenously daily . LTB4 activate stimulate various white blood cell activation release natural substance body process important part body 's defense infection .</brief_summary>
	<brief_title>A Pilot Study LTB4 HIV-1 Infected Adults</brief_title>
	<detailed_description>The objective pilot study investigate whether LTB4 , administer dose provide increase alfa-defensin release neutrophil , affect HIV viral load HIV-1 infected individual . The safety , tolerability effect assess 28 day daily intravenous dose LTB4 HIV viral load . Safety tolerability also assess . The study randomize , double-blind , placebo control . All subject randomly assign one three treamtent group , LTB4 two different dose level correspond placebo . Treatment duration 4 week follow-up period 2 week . Subjects visit clinic daily basis treatment period receive daily intravenous injection study drug . 40 subject enrol , seven clinic Canada participate study . Primary endpoint : Change viral load treatment period 28 day . Secondary endpoint : CD4 , CD8 neutrophil count , alfa-defensins CC-che , mokine release blood .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>1 . Male female subject 18 65 year age 2 . Diagnosis HIV1 infection 3 . Plasma HIV RNA level great equal 5,000 copies/mL screen visit 4 . A CD4 cell count equal great 250 cells/mm3 CD4 fraction equal great 14 % screen visit within one month study entry 5 . No ART within two month study entry 6 . Karnofsky score equal 80 7 . If female childbearing potential , negative serum pregnancy test screening . 8 . In opinion investigator , subject able comply requirement protocol , include ability present require visit 9 . Subject capable understanding signing informed consent form Exclusion criterion : 1 . Primary HIV1 infection 2 . Use investigational therapy precede month prior screen visit 3 . Prior screen entry study 4 . Use GCSF , GMCSF , IL2 , IFNs , erythropoietin , systemic inhaled steroid within one month screen visit 5 . HIVvaccine within one year screen visit 6 . Concurrent disease condition may present risk subject 7 . Females pregnant breast feed 8 . History malignancy active malignancy , except cutaneous Kaposis sarcoma 9 . Unexplained temperature 38.5 degree Celsius 10 . Chronic diarrhea ( &gt; 3 liquid stool per day persist 15 day ) within one month prior study entry 11 . Calculated creatinine clearance outside normal limit 12 . Urinalysis : hemoglobinuria , present 13 . Liver transaminases &gt; 3 x ULN 14 . Absolute neutrophil count &lt; 500/mm3 15 . Hemoglobin &lt; 8.0g/dL 16 . Platelet count &lt; 75,000/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Pilot study</keyword>
	<keyword>Randomized</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Effect viral load</keyword>
	<keyword>LTB4</keyword>
	<keyword>HIV-1 infection</keyword>
</DOC>